JP2021502404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502404A5 JP2021502404A5 JP2020542041A JP2020542041A JP2021502404A5 JP 2021502404 A5 JP2021502404 A5 JP 2021502404A5 JP 2020542041 A JP2020542041 A JP 2020542041A JP 2020542041 A JP2020542041 A JP 2020542041A JP 2021502404 A5 JP2021502404 A5 JP 2021502404A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- phosphatidylcholine
- nanoparticles
- composition
- liposomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 33
- 239000002502 liposome Substances 0.000 claims description 30
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 22
- 239000002105 nanoparticle Substances 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 15
- 230000003078 antioxidant effect Effects 0.000 claims description 15
- 235000006708 antioxidants Nutrition 0.000 claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- 230000010261 cell growth Effects 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 10
- 229960001231 choline Drugs 0.000 claims description 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 150000004291 polyenes Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570847P | 2017-10-11 | 2017-10-11 | |
| US62/570,847 | 2017-10-11 | ||
| PCT/US2018/055521 WO2019075277A1 (en) | 2017-10-11 | 2018-10-11 | COMPOSITIONS AND METHODS FOR TREATING FIBROSIS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502404A JP2021502404A (ja) | 2021-01-28 |
| JP2021502404A5 true JP2021502404A5 (https=) | 2021-11-18 |
| JP7379348B2 JP7379348B2 (ja) | 2023-11-14 |
Family
ID=66101109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542041A Active JP7379348B2 (ja) | 2017-10-11 | 2018-10-11 | 線維症の治療のための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12544394B2 (https=) |
| EP (1) | EP3694517A4 (https=) |
| JP (1) | JP7379348B2 (https=) |
| KR (1) | KR20200068692A (https=) |
| CN (1) | CN111278441A (https=) |
| AU (1) | AU2018347527B2 (https=) |
| CA (1) | CA3084359A1 (https=) |
| IL (1) | IL273850B1 (https=) |
| MX (1) | MX2020003718A (https=) |
| SG (1) | SG11202003300WA (https=) |
| WO (1) | WO2019075277A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY210343A (en) * | 2020-06-04 | 2025-09-12 | Hovid Berhad | Composition for normalisation of fatty liver and method for producing the same |
| EP4274566A4 (en) * | 2021-01-06 | 2024-10-30 | The Trustees of Indiana University | TOCOTRIENOL COMPOSITIONS AND METHODS FOR TREATING NONALCOHOLIC STEATOHEPATITIS |
| CN112587649A (zh) * | 2021-01-19 | 2021-04-02 | 中日友好医院(中日友好临床医学研究所) | 一种三肽化合物及其铜离子螯合物在预防和治疗矽肺中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1171047A (en) * | 1915-11-10 | 1916-02-08 | John Hornagy | Car-door fastener. |
| US2282236A (en) * | 1940-06-19 | 1942-05-05 | Bay State Optical Co | Eyeglass construction |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5284835A (en) * | 1992-07-31 | 1994-02-08 | Lieber Charles S | Use of dilinoleoylphosphatidylcholine (DLPC) for treatment and prevention of cirrhosis and fibrosis in the liver |
| AR002009A1 (es) * | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
| CA2181390C (en) * | 1995-07-18 | 2001-04-24 | Pankaj Modi | Phospholipid formulations |
| WO1997006784A1 (en) | 1995-08-15 | 1997-02-27 | Universite Libre De Bruxelles | Liposomes preparation method and plant |
| CA2282236A1 (en) * | 1998-11-06 | 2000-05-06 | Peter Stys | The use of excitatory amino acid transporter inhibitors to protect against cns white matter injury |
| US20040146516A1 (en) * | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| CN1518987A (zh) * | 2000-06-02 | 2004-08-11 | 大连万友贸易有限公司 | 多聚不饱和磷脂酰胆碱的新用途 |
| US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
| US20080107723A1 (en) * | 2006-09-28 | 2008-05-08 | Perkins Walter R | Methods of Treating Pulmonary Distress |
| JP5080779B2 (ja) | 2006-10-25 | 2012-11-21 | テルモ株式会社 | リポソーム製剤の製造方法 |
| WO2011009119A2 (en) | 2009-07-17 | 2011-01-20 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating fibrotic disorders |
| CA3102008A1 (en) | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US20160015656A2 (en) * | 2010-08-05 | 2016-01-21 | Nitto Denko Corporation | Composition for regenerating normal tissue from fibrotic tissue |
| US9585930B2 (en) | 2011-03-20 | 2017-03-07 | Trustees Of Boston University | Therapeutic agent for emphysema and COPD |
| CN102631330B (zh) * | 2012-04-19 | 2013-05-29 | 海南美大制药有限公司 | 一种兰索拉唑囊泡型磷脂凝胶缓释固体制剂 |
| HK1207977A1 (en) * | 2012-04-25 | 2016-02-19 | Trustees Of Tufts College | Silk microspheres and methods for surface lubrication |
| EP2874605A1 (en) | 2012-07-18 | 2015-05-27 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| KR20160125352A (ko) * | 2013-12-20 | 2016-10-31 | 이센셜 파마수티컬스 엘엘씨 | 세포 배양용 배지 |
| CN103816118A (zh) * | 2014-02-14 | 2014-05-28 | 西藏海思科药业集团股份有限公司 | 一种多烯磷脂酰胆碱注射用组合物及其制备方法 |
| KR20170107256A (ko) | 2016-03-15 | 2017-09-25 | 이진희 | 미백 화장료 조성물 |
| CN105997854B (zh) * | 2016-06-14 | 2018-11-27 | 成都天台山制药有限公司 | 多烯磷脂酰胆碱注射液组合物和制法 |
| CN106310220A (zh) | 2016-08-17 | 2017-01-11 | 浙江中医药大学 | 一种包封鳖甲肽的rgd‑ssl脂质体及其制备方法 |
-
2018
- 2018-10-11 JP JP2020542041A patent/JP7379348B2/ja active Active
- 2018-10-11 MX MX2020003718A patent/MX2020003718A/es unknown
- 2018-10-11 EP EP18867017.8A patent/EP3694517A4/en active Pending
- 2018-10-11 AU AU2018347527A patent/AU2018347527B2/en active Active
- 2018-10-11 CA CA3084359A patent/CA3084359A1/en active Pending
- 2018-10-11 US US16/755,245 patent/US12544394B2/en active Active
- 2018-10-11 CN CN201880070455.7A patent/CN111278441A/zh active Pending
- 2018-10-11 KR KR1020207012908A patent/KR20200068692A/ko active Pending
- 2018-10-11 SG SG11202003300WA patent/SG11202003300WA/en unknown
- 2018-10-11 WO PCT/US2018/055521 patent/WO2019075277A1/en not_active Ceased
-
2020
- 2020-04-06 IL IL273850A patent/IL273850B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2339846T3 (es) | Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob. | |
| Antushevich et al. | Apelin in disease | |
| JP6422855B2 (ja) | インスリンおよびインスリン類似体の薬物動態及び薬力学、ならびに注射部位の疼痛を調節するためのマグネシウム組成物 | |
| JP6066982B2 (ja) | 経口的に生物学的に利用可能な脂質ベースの構築物 | |
| TWI732156B (zh) | 用於治療和/或預防與肝炎病毒相關的疾病或病症的雙二氮雜雙環化合物 | |
| CN101677947A (zh) | 包含胰岛素衍生物的药物制剂 | |
| JPH09188658A (ja) | リポタンパク質およびクロトンアミドを含有する組成物 | |
| JP2021502404A5 (https=) | ||
| AU2006300046A2 (en) | Leucine rich composition | |
| JP7680746B2 (ja) | インクレチンミメティックが装填された脂質ナノカプセル | |
| JP2023510268A5 (https=) | ||
| JP2004505035A (ja) | 荷電脂質組成物及びその使用方法 | |
| EP4023663B1 (en) | Polypeptide and application thereof | |
| US10350272B2 (en) | Calcitonin analogues for treating diseases and disorders | |
| CN1200736C (zh) | 肝炎治疗剂 | |
| CN101969979A (zh) | 含有脱辅基水母蛋白的组合物及其使用方法 | |
| JP7379348B2 (ja) | 線維症の治療のための組成物および方法 | |
| JP2009539916A (ja) | ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用 | |
| Banik et al. | Core hydrophobicity tuning of a self-assembled particle results in efficient lipid reduction and favorable organ distribution | |
| CN105148257B (zh) | 促红细胞生成素来源肽在制备治疗代谢综合征的药物中的应用 | |
| CN1997383A (zh) | 含水母发光蛋白的组合物及使用它的方法 | |
| Su et al. | Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines | |
| CA2802388A1 (en) | Compositions and methods for treating cancer | |
| US20020155161A1 (en) | Use of IV emulsions with different triglyceride composition, particle size and apolipoprotein E for targeted tissue delivery of hydrophobic compounds | |
| Kamei et al. | Intranasal delivery |